Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 35

1.

Insights into molecular mechanism of action of salan titanium(IV) complex with in vitro and in vivo anticancer activity.

Miller M, Braitbard O, Hochman J, Tshuva EY.

J Inorg Biochem. 2016 Oct;163:250-257. doi: 10.1016/j.jinorgbio.2016.04.007.

PMID:
27090292
2.

Selenocysteine containing analogues of Atx1-based peptides protect cells from copper ion toxicity.

Shoshan MS, Lehman Y, Goch W, Bal W, Tshuva EY, Metanis N.

Org Biomol Chem. 2016 Aug 7;14(29):6979-84. doi: 10.1039/c6ob00849f.

PMID:
27349676
3.

Specific Design of Titanium(IV) Phenolato Chelates Yields Stable and Accessible, Effective and Selective Anticancer Agents.

Meker S, Braitbard O, Hall MD, Hochman J, Tshuva EY.

Chemistry. 2016 Jul 11;22(29):9986-95. doi: 10.1002/chem.201601389.

PMID:
27320784
4.

Effective Inhibition of Cellular ROS Production by MXCXXC-Type Peptides: Potential Therapeutic Applications in Copper-Homeostasis Disorders.

Shoshan MS, Tshuva EY.

Chemistry. 2016 Jun 27;22(27):9077-81. doi: 10.1002/chem.201601017.

PMID:
27124086
5.

Unbound position II in MXCXXC metallochaperone model peptides impacts metal binding mode and reactivity: Distinct similarities to whole proteins.

Shoshan MS, Dekel N, Goch W, Shalev DE, Danieli T, Lebendiker M, Bal W, Tshuva EY.

J Inorg Biochem. 2016 Jun;159:29-36. doi: 10.1016/j.jinorgbio.2016.02.016.

PMID:
26901629
6.

Highly Effective and Hydrolytically Stable Vanadium(V) Amino Phenolato Antitumor Agents.

Reytman L, Braitbard O, Hochman J, Tshuva EY.

Inorg Chem. 2016 Jan 19;55(2):610-8. doi: 10.1021/acs.inorgchem.5b02519.

PMID:
26699515
7.

Highly Stable Tetra-Phenolato Titanium(IV) Agent Formulated into Nanoparticles Demonstrates Anti-Tumoral Activity and Selectivity.

Meker S, Braitbard O, Margulis-Goshen K, Magdassi S, Hochman J, Tshuva EY.

Molecules. 2015 Oct 9;20(10):18526-38. doi: 10.3390/molecules201018526.

8.

Anti-proliferative activity of nano-formulated phenolato titanium(IV) complexes against cancer cells.

Meker S, Margulis-Goshen K, Weiss E, Braitbard O, Hochman J, Magdassi S, Tshuva EY.

ChemMedChem. 2014 Jun;9(6):1294-8. doi: 10.1002/cmdc.201400038.

PMID:
24677761
9.

C1-symmetrical titanium(IV) complexes of salan ligands with differently substituted aromatic rings: enhanced cytotoxic activity.

Glasner H, Tshuva EY.

Inorg Chem. 2014 Mar 17;53(6):3170-6. doi: 10.1021/ic500001j.

PMID:
24588655
10.

Structure and coordination determination of peptide-metal complexes using 1D and 2D ¹H NMR.

Shoshan MS, Tshuva EY, Shalev DE.

J Vis Exp. 2013 Dec 16;(82):e50747. doi: 10.3791/50747.

11.

Anticancer metal complexes: synthesis and cytotoxicity evaluation by the MTT assay.

Ganot N, Meker S, Reytman L, Tzubery A, Tshuva EY.

J Vis Exp. 2013 Nov 10;(81):e50767. doi: 10.3791/50767.

12.

Heteroleptic titanium(IV) catecholato/piperazine systems and their anti-cancer properties.

Hancock SL, Gati R, Mahon MF, Tshuva EY, Jones MD.

Dalton Trans. 2014 Jan 21;43(3):1380-5. doi: 10.1039/c3dt52583j.

PMID:
24201896
13.

A comparative chemical-biological evaluation of titanium(IV) complexes with a salan or cyclopentadienyl ligand.

Schur J, Manna CM, Deally A, Köster RW, Tacke M, Tshuva EY, Ott I.

Chem Commun (Camb). 2013 May 25;49(42):4785-7. doi: 10.1039/c3cc38604j.

PMID:
23598498
14.

Peptide models of Cu(I) and Zn(II) metallochaperones: the effect of pH on coordination and mechanistic implications.

Shoshan MS, Shalev DE, Tshuva EY.

Inorg Chem. 2013 Mar 18;52(6):2993-3000. doi: 10.1021/ic302404w.

PMID:
23458158
15.

High antitumor activity of highly resistant salan-titanium(IV) complexes in nanoparticles: an identified active species.

Meker S, Margulis-Goshen K, Weiss E, Magdassi S, Tshuva EY.

Angew Chem Int Ed Engl. 2012 Oct 15;51(42):10515-7. doi: 10.1002/anie.201205973.

PMID:
22961758
16.

Highly cytotoxic vanadium(V) complexes of salan ligands; insights on the role of hydrolysis.

Reytman L, Braitbard O, Tshuva EY.

Dalton Trans. 2012 May 7;41(17):5241-7. doi: 10.1039/c2dt11514j.

PMID:
22415291
17.

Cytotoxic salan-titanium(IV) complexes: high activity toward a range of sensitive and drug-resistant cell lines, and mechanistic insights.

Manna CM, Braitbard O, Weiss E, Hochman J, Tshuva EY.

ChemMedChem. 2012 Apr;7(4):703-8. doi: 10.1002/cmdc.201100593.

PMID:
22262543
18.

Cytotoxicity and hydrolysis of trans-Ti(IV) complexes of salen ligands: structure-activity relationship studies.

Tzubery A, Tshuva EY.

Inorg Chem. 2012 Feb 6;51(3):1796-804. doi: 10.1021/ic202092u.

PMID:
22220885
19.

Unexpected influence of stereochemistry on the cytotoxicity of highly efficient Ti(IV) salan complexes: new mechanistic insights.

Manna CM, Armony G, Tshuva EY.

Chemistry. 2011 Dec 9;17(50):14094-103. doi: 10.1002/chem.201102017.

PMID:
22076809
20.

A marked synergistic effect in antitumor activity of salan titanium(IV) complexes bearing two differently substituted aromatic rings.

Glasner H, Tshuva EY.

J Am Chem Soc. 2011 Oct 26;133(42):16812-4. doi: 10.1021/ja208219f.

PMID:
21967133

Supplemental Content

Loading ...
Support Center